Top

World Journal of Urology

Published in:

01-02-2010 | Original Article

Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction

Authors: Altug Tuncel, Varol Nalcacioglu, Kemal Ener, Yilmaz Aslan, Omur Aydin, Ali Atan

Published in: World Journal of Urology | Issue 1/2010

Abstract

Purpose

To evaluate the efficacy of sildenafil citrate only, 25 mg. Four times/week, tamsulosin only, 0.4 mg once daily, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostate hyperplasia (BPH) and erectile dysfunction.

Methods

A total of 60 men with BPH-related LUTS were randomized to receive sildenafil citrate only (n = 20), tamsulosin only (n = 20), and the combination of both (n = 20) for 8 weeks. Changes from baseline in International Prostate Symptom Score (IPSS), maximum urinary flow rate (Q _max), post voiding residual urine volume (PRV), Sexual Health Inventory for Male (SHIM) score, 3rd and 4th questions of International Index of Erectile Function (IIEF) were assessed at the end of the treatment.

Results

The mean age was 58 years. IPSS, Q _max, PRV, SHIM scores, and 3rd and 4th questions in IIEF significantly improved in each group. Improvement of IPSS was more remarkable in combination (40.1%) and tamsulosin only (36.2%) groups in comparison with sildenafil citrate only group (28.2%; p < 0.001). Improvement of Q _max and PRV were greater in tamsulosin only and combination than sildenafil citrate only group. SHIM scores significantly improved in sildenafil citrate only (65%) and combination (67.4%) than tamsulosin only (12.4%; p < 0.001). Increases in the 3rd and 4th questions of IIEF were greater in sildenafil only and combination than tamsulosin only (p < 0.001).

Conclusions

Treatment with the combination of tamsulosin only and sildenafil citrate only was not superior to tamsulosin only to enhance voiding symptoms. Also, sexual function improvement was similar for both the combination and sildenafil citrate only treatments.

Reynard JM, Peters TJ, Lamond E, Abrams P (1995) The significance of abdominal straining in men with lower urinary tract symptoms. Br J Urol 75:148–153CrossRefPubMed

Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158:481–487CrossRefPubMed

Norman RW, Nickel JC, Fish D, Pickett SN (1994) ‘Prostate-related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 74:542–550CrossRefPubMed

Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61PubMed

Girman CJ, Jacobsen SJ, Tsukamato T, Richard F, Garraway WM, Sagnier PP, Guess HA, Rhodes T, Boyle P, Lieber MM (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51:428–436CrossRefPubMed

Baniel J, Israilov S, Shmueli J, Segenreich H, Livne PM (2000) Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy. Eur Urol 38:53–58CrossRefPubMed

Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 12:305–311CrossRefPubMed

Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O’Leary MP, Puppo P, Robertson C, Giuliano F (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44:637–649CrossRefPubMed

Elliott SP, Gulati M, Pasta DJ, Spitalny GM, Kane CJ, Yee R, Lue TF (2004) Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology 63:1148–1152CrossRefPubMed

10.

Kaplan AS, Gonzales RR (2007) Phosphodiesterase type 5 inhibitors fort he treatment of male lower urinary tract symptoms. Rev Urol 9:73–77PubMed

11.

Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I (1998) The evaluation of sexual function in men presenting with benign prostatic hyperplasia. Br J Urol 82:842–846PubMed

12.

Roehrborn CG (2008) Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 10:14–25PubMed

13.

Kaminetsky JC (2006) Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin 22:2497–2506CrossRefPubMed

14.

Andersson KE (2001) Physiology of penile erection. Pharmacol Rev 53:417–450PubMed

15.

Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U (2002) Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction. Urology 59:281–286CrossRefPubMed

16.

Traish AM, Kim NN, Goldstein I, Moreland RB (1999) Alpha-adrenergic receptors in the penis. Identification, characterization, and physiological function. J Androl 20:671–682PubMed

17.

Francis SH, Blount MA, Zoraghi R, Corbin JD (2005) Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterase, and multi-drug anion transporters. Front Biosci 10:2097–2117CrossRefPubMed

18.

Uckert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484–2490CrossRefPubMed

19.

Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R (2006) Alpha-adrenoreceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 38:1–12CrossRefPubMed

20.

Andersson KE, Chapple CR, Hofner K (2002) Future drugs for he treatment of benign prostatic hyperplasia. World J Urol 19:436–442PubMed

21.

Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, Sale P, Berardi A, Petrangeli E, Gallucci M, Di Silverio F, Russo MA (1999) Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189:224–229CrossRefPubMed

22.

Bing W, Chang S, Hypolite JA, Di Santo ME, Zderic SA, Rolf L, Wein AJ, Chacko S (2003) Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 285:F990–F997PubMed

23.

Deedwania PC (2003) Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diabetes Rep 3:289–292CrossRef

24.

Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180:1228–1234CrossRefPubMed

25.

McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071–1077CrossRefPubMed

26.

Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy o twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53:1236–1244CrossRefPubMed

27.

Kaplan A, Gonzales RR, Te AE (2007) Combination of alfuzosin and sildenafil superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723CrossRefPubMed

28.

Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5:2170–2178CrossRefPubMed

29.

McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177:1401–1407CrossRefPubMed

Title: Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction
Authors: Altug Tuncel
Varol Nalcacioglu
Kemal Ener
Yilmaz Aslan
Omur Aydin
Ali Atan
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 1/2010
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-009-0484-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society

Application of a temporary ureter clamp for retroperitoneal laparoscopic ureterolithotomy

The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials

The difference in oxidative stress of the blood between using 5% glucose water and distilled water as the irrigant for BPH patients undergoing transurethral resection of the prostate

Four-arm robotic partial nephrectomy for complex renal cell carcinoma

Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH